Antibodies to infl iximab (ATIs) have been associated with loss of clinical response and lower serum infl iximab (IFX) levels in some studies of patients with infl ammatory bowel disease (IBD). This has important implications for patient management and development of novel biologic therapies. The objective of this study was to perform a systematic review and meta-analysis of studies that reported clinical outcomes and IFX levels according to patients ' ATI status.
INTRODUCTION
Infl iximab (IFX), a chimeric monoclonal antibody directed against tumor necrosis factor (TNF), is approved for the induction and maintenance of remission in both Crohn ' s disease (CD) and ulcerative colitis (UC) ( 1, 2 ) . Clinical trials and case series have reported induction of remission in 40 -60 % of patients treated with this agent, with the majority continuing with maintenance therapy every 8 weeks ( 2, 3 ) . Despite its proven effi cacy in maintenance of remission, a signifi cant proportion of patients lose their clinical response over time despite maintenance treatment ( 4 ) . Th is loss of response (LOR) occurs in up to 70 % of patients treated with IFX, and usually requires escalation of dosing or change in anti-TNF agent to re-capture clinical remission ( 5 -7 ) .
Th ere are several mechanisms of LOR to IFX; however, immunogenicity to the antibody itself appears to be a commonly identifi ed factor ( 8, 9 ) . Since IFX is a chimeric mouse -human IgG1 molecule,
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Infl ammatory Bowel Disease (IBD): A Meta-Analysis antibodies to IFX (antibodies to infl iximab (ATIs)) are primarily directed against the murine F(ab)2 fragment of the agent ( 10, 11 ) . ATIs are reported to develop in 8 -60 % of patients with infl ammatory bowel disease (IBD), depending on IFX dosing schedule, administration of concomitant steroids, or immunomodulators and the method of measuring ATI in the blood ( 10,12 -16 ) . Th ese antibodies can appear as soon as aft er the fi rst IFX infusion, and can persist in the blood stream for up to 1 -4.5 years even aft er discontinuation of IFX therapy ( 17, 18 ) .
Th e problem of immunogenicity of anti-TNF agents was not described in the early pivotal trials in IBD. It has since been observed that clearance of IFX is greatly increased in the presence of ATIs, and results in low IFX trough levels ( 10, 19, 20 ) . Low serum IFX concentrations have been associated with a lack of clinical response in both CD and UC ( 16, 21, 22 ) . Multiple studies in IBD patients have linked the development of ATI with loss of treatment response, shorter duration of response, and infusion reactions ( 10, 12, 15, 16, 23 ) . Conversely, others have shown no diff erence in clinical outcomes between ATI-positive or ATI-negative patients ( 14, 21 ) .
Th e association of ATIs with trough IFX levels and response to therapy with IFX has been inconsistent due to a lack of standardization of methods of measurement of serum IFX or antidrug antibodies. Th e presence of detectable drug in the serum typically impairs the performance of a solid-phase enzyme-linked immunosorbent assay (ELISA) and western blot ( 10 ) . With classic ELISA, antibodies remain undetectable as long as the drug is present in the blood. Th e type of detection assays also aff ects the reported incidence of ATIs ( 24 ) . Drug trough levels are less liable to interassay variations and may prove to be a more relevant surrogate marker for loss of clinical response than ATIs ( 25 ) . Although ATIs are well-described, other humanized therapeutic monoclonal antibodies that lack the murine F(ab) fragment are also associated with anti-drug antibodies ( 26 -28 ) .
For clinicians, patients, and developers of biologic agents, loss of clinical remission due to immunogenicity is a potential major limitation of this class of drug, leading to clinical relapse, impaired quality of life, and increased cost of care. In addition, the focus by regulatory authorities on the immunogenicity of pioneer biologics has implications for the future development and approval of generic biologics (so-called " biosimilars " ) ( 29, 30 ) . Although the potential negative impact of ATIs on trough IFX levels and clinical outcomes is widely acknowledged, no study has quantifi ed the extent of this eff ect via meta-analysis of raw data from published studies. In order to provide a pooled estimate of the impact of immunogenicity, we sought to perform a systematic review and meta-analysis of the impact of ATIs on clinical outcomes and serum IFX levels in patients with IBD.
METHODS

Literature search
A literature search was performed to identify all published and unpublished studies in any language for consideration for inclusion studies that had measured serum antibodies to IFX (ATI) and / or trough serum IFX levels and reported on clinical outcomes of IFX therapy in patients with IBD. A systematic search . Th e following search strategy was constructed by using a combination of MeSH subject headings and text-words relating to antibodies to IFX: " infl iximab, " " immunogenicity, " " anti-drug antibodies, " " infl iximab levels, " " antibodies to infl iximab (ATIs), " " human anti-chimeric antibodies (HACAs), " " ulcerative colitis, " " Crohn ' s disease, " " loss of response, " " remission. " Abstracts from American Digestive Diseases Week and the United European Gastroenterology Week (2002 -2011) were searched manually, and reference lists of all articles read and several previously published reviews were scrutinized to disclose additional literature on the topic.
Inclusion and exclusion criteria
We included all studies (controlled trials, observational studies, cohort studies) that reported prevalence of ATIs and clinical outcomes and / or serum IFX levels in patients who were treated with IFX for UC or CD. Th e primary outcome measure was " LOR, " defi ned as relapse of clinical symptoms in patients who were in clinical remission from, or had responded to, IFX. No pre-specifi ed Crohn ' s Disease Activity Index (CDAI) score was used to determine this outcome, as we expected there would be no universal defi nition of LOR across the studies. We did not require that included studies report the objective confi rmation of active infl ammation as the cause of symptoms. Th e included studies all came from experienced tertiary-referral IBD groups with extensive clinical trial history, and most reported exclusion of infection and / or biochemical confi rmation of infl ammation as part of their follow-up assessment of patients in their methods. Studies that measured ATIs by any method were included if they also reported clinical outcomes and / or serum IFX levels according to ATI status.
We excluded studies if they (i) were review articles (ii) examined IFX use in non-IBD patients, (iii) did not measure either ATI or IFX trough levels, (iv) did not report on numbers of patients who were ATI positive or negative, (v) did not report clinical outcomes of IFX therapy or serum IFX levels, and (vi) were studies using other anti-TNFs only (adalimumab or certolizumab).
Study selection
Two authors (K.S.N. and A.S.C.) independently scanned the abstract of every trial identifi ed by the search to determine eligibility. Blinding to source was not performed. Full articles were selected for further assessment if the abstract suggested the study included patients with CD or UC, ATIs or serum IFX were measured, and clinical outcomes were reported. If these criteria were unclear from the abstract, the full article was retrieved for clarifi cation. Papers not meeting the inclusion criteria were excluded. Any disagreements were resolved by discussion, and if required, by consultation with the senior author (A.C.M.).
Data extraction and quality assessment
Th e following data were retrieved (where possible) from published reports using standardized forms with disagreements REVIEW Nanda et al .
patients with IBD, and one that presented separate results for patients with UC and CD). Two studies reported combined data from both CD and UC patients and were thus classifi ed as " mixed IBD " for the purpose of meta-analysis. Th ree articles ( 21, 50, 51 ) met the criteria for inclusion, but did not report raw data in a manner suitable for inclusion in the meta-analysis.
Patients with CD were included in 11 studies ( n = 1,077). Length of follow-up in these studies ranged from 16 weeks to 3 years. In studies that reported the " number of IFX infusions, " the range was from 7 to 28 infusions. In the quality assessment of included studies, 7 / 11 (63 % ) of studies were graded 2 / 4 for quality and only 1 study (9 % ) graded 3 / 4 ( Supplementary Table 2 ).
Patients with UC were included in fi ve studies ( n = 301). Length of follow-up in these studies ranged from 14 months to 38 months, or a median of 8 -13 IFX infusions. In the quality assessment of included studies, 80 % of studies graded 2 / 4 for quality and one graded 3 / 4. Serum ATIs in the included studies were measured using several diff erent assays, including double antigen (DA) ELISA, antihuman λ chain ELISA, fl uid-phase RIA (radioimmunoassay), immunoaffi nity chromatography-based ELISA, and western blot ( Table 1 ) . Serum IFX levels in the included studies were measured using DA ELISA. Th e primary outcome for inclusion in this meta-analysis, " LOR, " was reported based on clinicians ' assessment, CDAI, or HBI (Harvey Bradshaw Index) in patients with CD, and clinicians ' assessment Partial Mayo score, or Simple Colitis Clinical Activity Index in patients with UC ( Table 1 ) .
Effects of ATIs on LOR
Ten studies of patients with IBD reported data on loss of clinical response according to ATI status, with data on a total of 668 patients ( Figure 1 ). Th e pooled RR of " loss of clinical response " in all patients with IBD treated with IFX who developed ATIs was 3.2 (95 % confi dence interval (CI): 2.0 -4.9, P < 0.0001). Th e number of patients needed to develop ATIs for one of them to lose response (NNH) was 3.
Seven studies of patients with CD were suitable for inclusion into a subgroup meta-analysis, with pooled data on 494 patients. Th e RR of LOR in patients with ATIs was 3.2 (95 % CI: 1.9 -5.5, P < 0.0001) when compared with patients without ATIs. Th e number of patients needed to develop ATIs for one of them to lose response (NNH) was 2. Th ere was statistical heterogeneity between the studies ( I 2 = 73 % ; P < 0.001). Two included studies were not suitable for the ATI meta-analysis; Maser et al. ( 21 ) was excluded from the meta-analysis due to the ambiguous clinical end point ( " percentage of patients that achieved the median duration of clinical remission " ), and Yamada et al. ( 50 ) due to the lack of reported ATI levels.
Only two studies reported raw data on the outcome of patients with UC alone, stratifi ed according to ATI status or IFX levels ( 22, 23 ) . Th e pooled RR of " loss of clinical response " in patients with UC treated with IFX who developed ATIs was 2.2 (95 % CI: 0.5 -9). However, the test for overall eff ect was non-signifi cant ( P = 0.3), and there was signifi cant statistical heterogeneity between the two studies ( I 2 = 80 % ; P < 0.03).
resolved by discussion between the reviewers: number of patients in the study, method of selection of cohorts, schedule of anti-TNF administration, assay type used to measure ATI, numbers of ATI-positive and -negative patients, mean (s.d.) and median (interquartile range) IFX trough levels, methods of measurement of clinical outcomes, and reporting outcomes used. Assessment of quality of randomized controlled trials and observational studies was performed using Th e GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria ( 31 ) . For observational studies, methodological quality was assessed by determining the eligibility criteria, degree of measurement of both exposure and outcome, control for confounders, and completeness of follow-up ( 32 ) .
Statistical analysis
Data were analyzed and reported consistent with the consensus guidelines by the Meta-analysis of Observational Studies in Epidemiology group ( 33 ) . Data were pooled for meta-analysis if the outcomes were suffi ciently similar (determined by consensus of authors) and data were homogenous (determined by the degree of clinical and statistical heterogeneity). Data were pooled for metaanalysis if the criteria for " LOR " in each study were determined by consensus to represent clinically comparable events in the context of disease activity. Raw data from included studies (absolute numbers) were used to construct 2 × 2 contingency tables, and unadjusted risk ratios (RRs) were calculated using Review Manager (RevMan 5.1, Nordic Cochrane Centre, Copenhagen, Denmark) for dichotomous outcomes. Standardized mean diff erence was used to report the summary statistic for comparison of outcomes presented as continuous scales, to account for diff erence in methods of measurement of IFX levels and ATIs. Th e random eff ects model was used to account for variations between studies and give a more conservative pooled estimate ( 34 ) . Th e Q test was used to assess for heterogeneity and I 2 statistic to quantify the percentage of heterogeneity due to betweenstudy variation; a value of P < 0.10 was considered statistically signifi cant ( 35 ) . Funnel plots and the Egger ' s test were used to evaluate for publication bias ( 36 ) . Th e NNH (number needed to harm) was calculated where informative ( 37 ) . Sensitivity analyses were performed for all outcomes where three or more studies were included. Sensitivity analysis included sensitivity based on individual studies, sample size, method or ATI determination, episodic or scheduled IFX, length of study. Signifi cance levels were set at a P < 0.05.
RESULTS
Study characteristics
Supplementary Figure 1 illustrates the study selection process; of the 99 references identifi ed from database searches, 29 articles were selected for full text review. From these, only 13 articles were deemed suitable and met the pre-specifi ed inclusion criteria. Sixteen articles / abstracts were excluded for various reasons detailed in Supplementary Table 1 ( 12,15,17,18,38 -48,49 ) . 
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Two studies reported results in a mixed population of patients with IBD, both CD and UC ( 10, 20 ) . Th e prevalence of ATI ranged from 22.4 to 46 % . RR of LOR in the presence of ATIs was 6.9 (95 % CI: 1.9 -25; P < 0.003). NNH calculated was 3. Th ere was no statistical heterogeneity between the two studies ( I 2 = 0 % ; P < 0.5). Finally, the prior analyses grouped patients according to dichotomous ATI status (present / absent). Four studies reported mean / median ATI absolute levels according to patients ' clinical outcomes and all concluded that patients who lost response had significantly higher ATI levels than patients who maintained remission ( Supplementary Table 3 ). Th ese data were not suitable for meta-analysis due to the lack of reporting of means and standard deviations in all studies.
Effects of ATIs on serum IFX levels
Th e eff ect of ATI status on serum IFX levels was reported in one study of patients with CD ( n = 58), and two studies that pooled patients with UC and CD together ( n = 185). All three studies reported signifi cantly lower trough serum IFX levels in patients with detectable ATIs. Raw data on mean or median trough IFX levels according to ATI status are summarized in Table 2a . A meta-analysis of the pooled standardized mean diff erence confi rmed a signifi cant diff erence in trough serum IFX levels between ATI + and ATI − patients (standardized mean diff erence − 0.8, 95 % CI: − 1.2, − 0.4, P < 0.0001, random eff ects model) ( Figure 2 ).
Since low serum IFX levels have also been associated with LOR to IFX, we also examined the serum IFX levels according to LOR in patients with IBD. Raw data on trough IFX levels according to maintenance of response to therapy were reported in six studies in patients with IBD; four reported signifi cant diff erences in serum IFX level according to clinical outcomes, but two did not. Median or mean IFX levels in each group are provided in Table 2b . Only one study reported mean and standard deviation for serum IFX levels, so these data were not suitable for performing a meta-analysis of the results.
Sensitivity analysis
Sensitivity analysis was performed for the overall eff ect estimate for outcomes where there were >3 studies in a meta-analysis (LOR in all IBD patients, and in those with CD only). Exclusion of studies that showed no signifi cant diff erence in LOR according to ATI status ( 14,23,52 ) increased the pooled eff ect estimate ( Supplementary Table 4A and B ). Analyses based on eff ect estimates (fi xed or random), IFX schedule (episodic or scheduled), type of ATI assay (RIA or DA ELISA), criteria for LOR (physicians ' assessment or CDAI / HBI, reported exclusion of other causes of symptoms) did chance from real asymmetry if < 10 studies are included ( 53 ) . Th e overall appearance of the funnel plot suggests an inverse linear association between precision and eff ect size; the most precise studies (the ones with larger size and more events) produced RRs closer to 1 (no eff ect).
DISCUSSION
Th e association between clinical effi cacy with anti-TNF-α drug levels and the presence of ATI has been examined by a number of groups, with inconsistent results ( 54 ) . Th e development of ATI and low serum IFX concentrations have been implicated as important cause of therapeutic failure in patients receiving IFX ( 12, 16, 22, 23 ) . Th ere is ongoing debate as to the relevance of ATI development in clinical care; two recent systematic reviews came to diff erent conclusions on the signifi cance of ATIs on clinical outcomes ( 9, 55 ) . Our study is the fi rst meta-analysis to investigate the pooled impact of immunogenicity on clinical outcomes with IFX therapy in patients with IBD. We found an association between ATI and LOR to therapy in our meta-analysis involving 10 studies and 668 patients. Overall, patients with IBD on IFX who develop ATI have a threefold risk of LOR to therapy. Th ere was signifi cant heterogeneity among the studies, which implies that the summary RR should be interpreted with caution. On subgroup and sensitivity analyses, the positive association between ATI and LOR was retained. Th e presence of ATI is also associated with lower serum IFX levels in the pooled not signifi cantly change the eff ect estimate. No adjusted data were reported in the included studies for further subgroup analyses.
In order to identify the determinants of the statistical heterogeneity seen in the main subgroup analysis (CD), each individual study was excluded, and the I 2 value measured for heterogeneity. Exclusion of the Imaeda and Steenholdt studies lowered the I 2 result to 40 % (heterogeneity " might not be important " ) ( 35 ) . Th e RR for the eff ect of ATIs decreased to 2.2 (95 % CI: 1.5 -3.4, P = 0.0002) when these studies were excluded.
Test for publication bias
Th e funnel plot (standard error by RR) for publication bias is illustrated in Figure 3 . Formal tests for funnel plot asymmetry were not performed as the power of these tests is too low to distinguish 
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results of two studies. Lower IFX levels were associated with LOR in three of fi ve studies that examined this topic, but these data were not suitable for meta-analysis. Th e link between immunogenicity and LOR was fi rst reported by Baert et al. ( 12 ) . Th ey demonstrated that the presence of ATI was associated with a shorter duration of clinical response. Since then numerous other observational and randomized controlled trial have investigated this association with confl icting results. Ben-Horin et al. ( 17 ) showed that in their cohort of 62 patients on scheduled IFX dosing, LOR was associated with higher frequency of ATI (78 vs. 17 % no LOR, P < 0.01). Maser et al. ( 21 ) performed a study on CD patients, most of who were on scheduled maintenance treatment with IFX and found no diff erence in the duration of clinical response in patients with detectable IFX serum levels with or without ATIs (66 vs. 67 % ). A subanalysis of ACCENT 1 data showed that remission rates at 54 weeks were similar (41 and 39 % ) in patients who were ATI-positive and ATI-negative ( 14 ) .
Higher IFX trough levels have been associated with sustained clinical remission in several studies. Seow et al. ( 23 ) showed that in their UC population of 106 patients treated with scheduled IFX dosing, detectable IFX trough was associated with signifi cant positive predictive value for clinical remission, endoscopic improvement, and avoidance of colectomy (all P < 0.001). Similarly, Maser et al. ( 21 ) showed that in a subgroup of 90 patients on maintenance therapy, higher IFX levels were associated with improved clinical remission, CRP, and endoscopic healing ( P < 0.001). Steenholdt et al. ( 22 ) investigated 106 mixed IBD patients and found that higher median IFX trough levels were associated with maintenance of response ( P < 0.0001). Th ey were also able to determine clinically relevant threshold values for trough IFX and ATI concentrations. However, Pariente et al. ( 20 ) , in a retrospective study of 76 IBD patients, 39 of whom had dose intensifi cation of IFX following initial non-response to therapy, showed no diff erence in mean IFX trough between patients who responded (69 % ) to dose intensifi cation vs. those who did not.
Th e strength of our study lies in the uniform selection criteria used for including studies in the meta-analysis. We chose to focus on studies that reported prevalence of ATIs according to clinical outcomes and / or serum IFX levels in patients who were treated with maintenance IFX. We chose a primary end point that could clinically be comparable across similar patient population studies, therefore excluding some studies ( 12, 21, 49 ) . We also performed an assessment of study quality using the GRADE criteria ( 32 ) .
As with all meta-analyses, caution needs to be used when making conclusions based on pooled studies with heterogeneous patient populations. In this context, we have included studies that did not share universal methods for enrolling or determining the primary end point, and used diff erent methods for detection of ATIs. To incorporate for clinical heterogeneity, we only extracted data on patients receiving maintenance therapy, and assumed that " LOR " looks similar in practice, whether measured with CDAI, HBI, Mayo score, or a physician ' s assessment. It has been noted by others that a physician ' s global assessment of clinical status correlates well with more complicated disease activity scores such as the CDAI ( 56 ) . To incorporate for statistical heterogeneity in the metaanalysis, we used a random eff ects model to analyze all outcomes, and used standardized mean diff erence for reporting continuous outcomes. We also performed subgroup and sensitivity analyses to examine diff erences in the overall eff ect estimate ( 57 ) . It should also be noted that all included studies were judged to be at " high risk " of bias in at least one quality domain ( Supplementary Table 2 ). In addition, the funnel plot ( Figure 3 ) is asymmetric, suggesting a publication bias in this literature.
It should be noted that we did not extract data for analysis on patients who were ATI inconclusive (ATI negative but IFX detectable). Th ere is evidence that ATI inconclusive patients tend not to have early LOR; however, it may be an indicator for future potential LOR ( 52 ). Maser et al. ( 21 ) showed that ATI inconclusive group had longer median duration of clinical remission (100 % ) compared Specifi c author contributions : Acquisition of data, analysis and interpretation of data, and wrote the manuscript: Kavinderjit S. Nanda; critical revision of the manuscript for important intellectual content: Adam S. Cheifetz; study concept and design, critical revision of the manuscript for important intellectual content, statistical analysis, and study supervision: Alan C. Moss. All authors discussed the results and implications and commented on the manuscript at all stages. Financial support: A.C.M. has served on Advisory Boards for Janssen, Abbott, and UCB, and acted as a consultant on an unrelated study for Prometheus Laboratories and SQI Laboratories. He was supported by NIH Grant K23DK084338. KSN is an IBD fellow at BIDMC, supported by an unrestricted educational grant to the Mater Misericordiae University Hospital by MSD (Ireland). Potential competing interests : None.
with both ATI-positive (66 % ) and ATI-negative groups (67 % ) ( P < 0.001). Similar observations have been made by Colombel et al. ( 38 ) , whereby this ATI result was associated with higher steroid free remission rates and Seow et al. ( 23 ) showing improved remission rates, endoscopic improvement and reduced colectomy rates. Others have shown ATI inconclusive patients do not diff er to ATIpositive or -negative patients in terms of clinical outcomes ( 14 ) . Th e higher remission rate for ATI inconclusive patients is likely related to higher serum IFX concentrations relative to ATI-positive or -negative patients. Kopylov et al. ( 52 ) showed that in their study, LOR in ATI inconclusive patients was only associated with low IFX levels in 50 % of the cases, which indicates the possibility of an alternative, non-immune mediated pathway for development of LOR. As previously described, the presence of ATI can impede the clinical response by aff ecting the drug ' s bioavailability, pharmacokinetics, and pharmacodynamics ( 51 ) . Th e true incidence of ATI in IBD patients treated with IFX remains unknown due to the diff erent administration schedules, timing of ATI measurements, methods used in ATI detection, and the presence of serum IFX.
In conclusion, the present meta-analysis quantifi es the impact of ATIs on maintenance of clinical remission in patients with IBD; patients on IFX therapy who develop ATI have a threefold higher increased risk of LOR to therapy compared with those who do not develop ATIs. ATI development is also associated with lower serum IFX levels in these patients. Th is has implications for the management of patients on biologic therapy, and the development of biosimilars.
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